Literature DB >> 20652688

High-throughput simultaneous analysis of buprenorphine, methadone, cocaine, opiates, nicotine, and metabolites in oral fluid by liquid chromatography tandem mass spectrometry.

Marta Concheiro1, Teresa R Gray, Diaa M Shakleya, Marilyn A Huestis.   

Abstract

A method for simultaneous determination of buprenorphine (BUP), norbuprenorphine (NBUP), methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), cocaine, benzoylecgonine (BE), ecgonine methyl ester (EME), anhydroecgonine methyl ester (AEME), morphine, codeine, 6-acetylmorphine (6AM), heroin, 6-acetylcodeine (6AC), nicotine, cotinine, and trans-3'-hydroxycotinine (OH-cotinine) by liquid chromatography tandem mass spectrometry in oral fluid (OF) was developed and extensively validated. Acetonitrile (800 μL) and OF (250 μL) were added to a 96-well Isolute-PPT+protein precipitation plate. Reverse-phase separation was achieved in 16 min and quantification was performed by multiple reaction monitoring. The assay was linear from 0.5 or 1 to 500 μg/L. Intraday, interday, and total imprecision were less than 13% (n = 20), analytical recovery was 92-114% (n = 20), extraction efficiencies were more than 77% (n = 5), and process efficiencies were more than 45% (n = 5). Although ion suppression was detected for EME, cocaine, morphine, 6AC, and heroin (less than 56%) and enhancement was detected for BE and nicotine (less than 316%), deuterated internal standards compensated for these effects. The method was sensitive (limit of detection 0.2-0.8 μg/L) and specific (no interferences) except that 3-hydroxy-4-methoxyamphetamine interfered with AEME. No carryover was detected, and all analytes were stable for 24 h at 22 °C, for 72 h at 4 °C, and after three freeze-thaw cycles, except cocaine, 6AC, and heroin (22-97% loss). The method was applied to 41 OF specimens collected throughout pregnancy with a Salivette® OF collection device from an opioid-dependent BUP-maintained pregnant woman. BUP ranged from 0 to 7,400 μg/L, NBUP from 0 to 71 μg/L, methadone from 0 to 3 μg/L, nicotine from 32 to 5,020 μg/L, cotinine from 125 to 508 μg/L, OH-cotinine from 11 to 51 μg/L, cocaine from 0 to 419 μg/L, BE from 0 to 351 μg/L, EME from 0 to 286 μg/L, AEME from 0 to 7 μg/L, morphine from 0 to 22 μg/L, codeine from 0 to 1 μg/L, 6AM from 0 to 4 μg/L, and heroin from 0 to 2 μg/L. All specimens tested negative for EDDP and 6AC. This method permits a fast and simultaneous quantification of 16 drugs and metabolites in OF, with good selectivity and sensitivity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20652688      PMCID: PMC3163083          DOI: 10.1007/s00216-010-3903-5

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  20 in total

1.  Drug screening of preserved oral fluid by liquid chromatography-tandem mass spectrometry.

Authors:  Elisabeth Leere Øiestad; Unni Johansen; Asbjorg Solberg Christophersen
Journal:  Clin Chem       Date:  2006-12-07       Impact factor: 8.327

2.  Liquid chromatography/tandem mass spectrometry for the qualitative and quantitative analysis of illicit drugs and medicines in preserved oral fluid.

Authors:  Susana Sadler Simões; Antonio Castañera Ajenjo; João Miguel Franco; Duarte Nuno Vieira; Mário João Dias
Journal:  Rapid Commun Mass Spectrom       Date:  2009-05       Impact factor: 2.419

3.  Drug testing in oral fluid-evaluation of sample collection devices.

Authors:  Kaarina Langel; Charlotta Engblom; Anna Pehrsson; Teemu Gunnar; Kari Ariniemi; Pirjo Lillsunde
Journal:  J Anal Toxicol       Date:  2008 Jul-Aug       Impact factor: 3.367

4.  Multiclass analysis of illicit drugs in plasma and oral fluids by LC-MS/MS.

Authors:  M Sergi; E Bafile; D Compagnone; R Curini; G D'Ascenzo; F S Romolo
Journal:  Anal Bioanal Chem       Date:  2008-11-04       Impact factor: 4.142

5.  Determination of illicit and medicinal drugs and their metabolites in oral fluid and preserved oral fluid by liquid chromatography-tandem mass spectrometry.

Authors:  Marta Concheiro; Ana de Castro; Oscar Quintela; Angelines Cruz; Manuel López-Rivadulla
Journal:  Anal Bioanal Chem       Date:  2008-05-16       Impact factor: 4.142

6.  How to improve estimates of imprecision.

Authors:  J S Krouwer; R Rabinowitz
Journal:  Clin Chem       Date:  1984-02       Impact factor: 8.327

7.  Optimization and validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of nicotine, cotinine, trans-3'-hydroxycotinine and norcotinine in human oral fluid.

Authors:  Diaa M Shakleya; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2009-10-18       Impact factor: 4.142

Review 8.  Oral fluid testing for drugs of abuse.

Authors:  Wendy M Bosker; Marilyn A Huestis
Journal:  Clin Chem       Date:  2009-09-10       Impact factor: 8.327

9.  Determination of nicotine, cotinine, and related alkaloids in human urine and saliva by automated in-tube solid-phase microextraction coupled with liquid chromatography-mass spectrometry.

Authors:  Hiroyuki Kataoka; Reiko Inoue; Katsuharu Yagi; Keita Saito
Journal:  J Pharm Biomed Anal       Date:  2008-10-08       Impact factor: 3.935

10.  Validation of analysis of amphetamines, opiates, phencyclidine, cocaine, and benzoylecgonine in oral fluids by liquid chromatography-tandem mass spectrometry.

Authors:  Subbarao V Kala; Steve E Harris; Tom D Freijo; Stan Gerlich
Journal:  J Anal Toxicol       Date:  2008-10       Impact factor: 3.367

View more
  2 in total

1.  A validated workflow for drug detection in oral fluid by non-targeted liquid chromatography-tandem mass spectrometry.

Authors:  Vera Reinstadler; Stefan Lierheimer; Michael Boettcher; Herbert Oberacher
Journal:  Anal Bioanal Chem       Date:  2018-12-06       Impact factor: 4.142

2.  Stability of Cocaine, Opiates, and Metabolites in Dried Saliva Spots.

Authors:  Ema Almeida; Sofia Soares; Joana Gonçalves; Tiago Rosado; Nicolás Fernández; Jesus M Rodilla; Luís A Passarinha; Mário Barroso; Eugenia Gallardo
Journal:  Molecules       Date:  2022-01-19       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.